Stabalised 99mTc compositions

Patent metadata

Field	Value
Publication number	US-9694092-B2
Application number	US-72106405-A
Country	US
Kind code	B2
Filing date	Oct 14, 2005
Priority date	Dec 15, 2004
Publication date	Jul 4, 2017
Grant date	Jul 4, 2017

Abstract

The present invention relates to stabilised 99m Tc radiopharmaceutical compositions of the ligand tetrofosmin, which include an ascorbic acid or ascorbate radioprotectant, in the absence of an antimicrobial preservative. The invention also provides lyophilised kits suitable for the bulk preparation of multiple unit patient doses of 99m Tc-tetrofosmin metal complexes. Also disclosed are unit doses of 99m Tc-tetrofosmin, together with processes for preparing such unit doses from the lyophilised bulk vial.

First claim

The invention claimed is:

1. A lyophilised, non-radioactive formulation in a single container, said formulation consisting of:
(i) tetrofosmin;
(ii) a radioprotectant selected from ascorbic acid or a salt thereof with a biocompatible cation;
(iii) a biocompatible reductant;
(iv) an effective amount of a pH-adjusting agent; and
(v) at least one transchelator;
with the proviso that an antimicrobial preservative is not present in the container and wherein the formulation having a pH in the range of 8.0 to 9.2.

2. The formulation of claim 1 , wherein the at least one transchelator is selected from 5-sulfosalicylic acid and gluconic acid or salts thereof with a biocompatible cation.

3. The formulation of claim 1 , wherein the biocompatible reductant comprises stannous ion.

4. The formulation of claim 1 , wherein the pH-adjusting agent is sodium bicarbonate, sodium hydrogen carbonate, or a combination thereof.

5. The formulation of claim 1 , wherein the container is a sealed, sterile multi-dose container fitted with a closure which permits addition and withdrawal of solutions whilst maintaining sterile integrity.

6. The multi-dose container of claim 5 , wherein the container is a septum-sealed vial of 20 to 40 cm 3 volume.

7. A non-radioactive kit, comprising the formulation in the container of claim 1 .

8. A lyophilised, non-radioactive formulation in a single container, said formulation consisting of:
(i) tetrofosmin;
(ii) a radioprotectant selected from ascorbic acid or a salt thereof with a biocompatible cation;
(iii) a biocompatible reductant comprising a stannous ion;
(iv) an effective amount of a pH-adjusting agent; and
(v) at least one transchelator selected from 5-sulfosalicylic acid and gluconic acid or salts thereof with a biocompatible cation;
with the proviso that an antimicrobial preservative is not present in the container and wherein the formulation having a pH in the range of 8.0 to 9.2.

9. A non-radioactive kit, comprising the formulation of claim 8 .

10. The formulation of claim 8 , wherein the pH-adjusting agent is sodium bicarbonate, sodium hydrogen carbonate, or a combination thereof.

11. The formulation of claim 8 , wherein the container is a sealed, sterile multi-dose container fitted with a closure which permits addition and withdrawal of solutions whilst maintaining sterile integrity.

12. The multi-dose container of claim 11 , wherein the container is a septum-sealed vial of 20 to 40 cm 3 volume.

13. A lyophilised, non-radioactive formulation in a single container, said formulation consisting of:
(i) tetrofosmin;
(ii) a radioprotectant selected from ascorbic acid or a salt thereof with a biocompatible cation;
(iii) a biocompatible reductant comprising a stannous ion;
(iv) an effective amount of sodium carbonate, sodium hydrogen carbonate, or a combination thereof as pH adjusting agent; and
(v) at least one transchelator selected from 5-sulfosalicylic acid and gluconic acid or salts thereof with a biocompatible cation;
with the proviso that an antimicrobial preservative is not present in the container, wherein the formulation having a pH in the range of 8.0 to 9.2,
wherein the container is a septum-sealed, sterile multi-dose container, having a volume of 20 to 40 cm 3 and fitted with a closure which permits addition and withdrawal of solutions whilst maintaining sterile integrity.

14. A non-radioactive kit, comprising the formulation of claim 13 .

Assignees

• Hjelstuen Ole Kristian
• Martinussen Grethe Karin
• Stensrud Gry
• Ge Healthcare Ltd

Inventors

• Hjelstuen Ole Kristian
• Martinussen Grethe Karin
• Stensrud Gry

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K51/0497 Primary

  conjugates with a carrier being an organic compounds · CPC title

• A61K51/02 Primary

  characterised by the carrier {, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus} · CPC title